Sex Differences in Antidepressant Acceptability According to Filled Prescription Sequences in a Nationwide Cohort Study

Charles Ouazana Vedrines, MD ; Nicolas Hoertel, MD, PhD ; Thomas Lesuffleur, MSc ; Pierre Denis, MSc ; Mark Olfson, MD, PhD ; Carlos Blanco, MD, PhD ; Frédéric Limosin, MD, PhD ; Antoine Rachas, MD, PhD ; Philippe Tuppin, MD, PhD ; Cédric Lemogne, MD, PhD

J Clin Psychiatry 2024;85(4):23m15128

Abstract

Objective: The prevalence of depressive and anxiety disorders is higher in women than in men. In contrast, there is still no clear consensus on the existence of sex-related differences in the effectiveness of antidepressant treatments for these disorders. This real-world study used filled prescription sequences to compare antidepressant medications between women and men at a medication level according to their acceptability (ie, combination of efficacy and tolerability).

Methods: In a nationwide cohort from the French national health data system (Système National des Données de Santé [SNDS]), 1.2 million people were identified as new antidepressant users for any condition in 2011. The outcome was clinical acceptability as measured by the continuation/change ratio over the 6- month period following the introduction of the first-line treatment. Continuation was defined as at least 2 refills of the same treatment. Change was defined as at least one filled prescription of another antidepressant, an antipsychotic medication, or a mood stabilizer. Adjusted odds ratios (aORs) were computed through multivariable binary logistic regressions.

Results: Overall, after the first prescription of an antidepressant, the continuation/ change ratio was slightly higher for women than men (aOR [95% CI], 1.06 [1.05–1.08]), with escitalopram ranking first in both. Sex-by-medication interactions were significant for paroxetine (0.91 [0.88–0.95]) and fluoxetine (1.19 [1.12–1.26]) only. Specifically, fluoxetine was significantly more acceptable in female than in male participants (0.73 [0.70–0.75] vs 0.63 [0.60–0.67]), whereas paroxetine was more acceptable in male than in female participants (0.75 [0.72–0.78] vs 0.68 [0.66–0.70]).

Conclusion: These real-world data may help practitioners and policymakers prioritize choice of antidepressant medications in women and men.

J Clin Psychiatry 2024;85(4):23m15128

Author affiliations are listed at the end of this article.

Continue Reading...

Members enjoy unlimited free PDF downloads as part of their subscription! Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Buy PDF for $40

Please sign in or purchase this PDF for $40.

References (59)

Cuijpers P, Vogelzangs N, Twisk J, et al. Comprehensive meta-analysis of excess mortality in depression in the general community versus patients with specific illnesses. Am J Psychiatry. 2014;171:453–462. PubMed CrossRef
GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137–150. PubMed CrossRef
Penninx BW, Pine DS, Holmes EA, et al. Anxiety disorders. Lancet. 2021;397:914–927. PubMed CrossRef
Blanco C, Wall MM, Hoertel N, et al. Psychiatric disorders and risk for multiple adverse outcomes: a national prospective study. Mol Psychiatry. 2021;26(3):907–916. PubMed CrossRef
Hoertel N, Franco S, Wall MM, et al. Mental disorders and risk of suicide attempt: a national prospective study. Mol Psychiatry. 2015;20(6):718–726. PubMed CrossRef
National Institute for Health and Care Excellence. Depression in adults: treatment and management (NICE guideline NG222). National Institute for Health and Care Excellence. 2022. https://www.nice.org.uk/guidance/ng222/resources/depression-in-adults-treatment-and-management-pdf-66143832307909.
Agence Nationale de Sécurité du Médicament et des Produits de Santé. Traitement par antidépresseurs. ANSM. 2019. https://archive.ansm.sante.fr/Dossiers/Traitementspar-antidepresseurs/Traitement-par-antidepresseurs/(offset)/0.
Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019;393:768–777. PubMed CrossRef
Iacobucci G. NHS prescribed record number of antidepressants last year. BMJ. 2019;364:l1508. PubMed CrossRef
Bogowicz P, Curtis HJ, Walker AJ, et al. Trends and variation in antidepressant prescribing in English primary care: a retrospective longitudinal study. BJGP Open. 2021;5(4):BJGPO.2021.0020. PubMed CrossRef
Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299–2312. PubMed CrossRef
Dold M, Kasper S. Evidence-based pharmacotherapy of treatment-resistant unipolar depression. Int J Psychiatry Clin Pract. 2017;21(1):13–23. PubMed
MacQueen G, Santaguida P, Keshavarz H, et al. Systematic review of clinical practice guidelines for failed antidepressant treatment response in major depressive disorder, dysthymia, and subthreshold depression in adults. Can J Psychiatry. 2017;62(1):11–23. PubMed
Malhi GS, Bell E, Singh AB, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: major depression summary. Bipolar Disord. 2020;22(8):788–804. PubMed CrossRef
Boyce P, Hopwood M, Morris G, et al. Switching antidepressants in the treatment of major depression: when, how and what to switch to? J Affect Disord. 2020;261:160–163. PubMed
Gabriel FC, de Melo DO, Fráguas R, et al. Pharmacological treatment of depression: a systematic review comparing clinical practice guideline recommendations. PLoS One. 2020;15(4):e0231700. PubMed CrossRef
Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40. PubMed
Platt JM, Bates L, Jager J, et al. Is the US gender gap in depression changing over time? A meta-regression. Am J Epidemiol. 2021;190(7):1190–1206. PubMed
Kessler RC. Epidemiology of women and depression. J Affect Disord. 2003;74(1):5–13. PubMed
Marcus SM, Young EA, Kerber KB, et al. Gender differences in depression: findings from the STAR*D study. J Affect Disord. 2005;87(2–3):141–150. PubMed CrossRef
Young MA, Scheftner WA, Fawcett J, et al. Gender differences in the clinical features of unipolar major depressive disorder. J Nerv Ment Dis. 1990;178(3):200–203. PubMed CrossRef
Sutin AR, Zonderman AB. Depressive symptoms are associated with weight gain among women. Psychol Med. 2012;42(11):2351–2360. PubMed CrossRef
Anderson JC, Williams S, McGee R, et al. DSM-III disorders in preadolescent children. Prevalence in a large sample from the general population. Arch Gen Psychiatry. 1987;44(1):69–76. PubMed CrossRef
Sramek JJ, Murphy MF, Cutler NR. Sex differences in the psychopharmacological treatment of depression. Dialogues Clin Neurosci. 2016;18(4):447–457. PubMed CrossRef
LeGates TA, Kvarta MD, Thompson SM. Sex differences in antidepressant efficacy. Neuropsychopharmacology. 2019;44(1):140–154. PubMed CrossRef
Yang SJ, Kim SY, Stewart R, et al. Gender differences in 12-week antidepressant treatment outcomes for a naturalistic secondary care cohort: the CRESCEND study. Psychiatry Res. 2011;189(1):82–90. PubMed
Berlanga C, Flores-Ramos M. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. J Affect Disord. 2006;95(1–3):119–123. PubMed
Frank E, Carpenter LL, Kupfer DJ. Sex differences in recurrent depression: are there any that are significant? Am J Psychiatry. 1988;145(1):41–45. PubMed
Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000;157:1445–1452. PubMed CrossRef
Hildebrandt MG, Steyerberg EW, Stage KB, et al. Are gender differences important for the clinical effects of antidepressants? Am J Psychiatry. 2003;160(9):1643–1650. PubMed CrossRef
Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 2001;62(11):869–877. PubMed CrossRef
Parker G, Parker K, Austin MP, et al. Gender differences in response to differing antidepressant drug classes: two negative studies. Psychol Med. 2003;33(8):1473–1477. PubMed CrossRef
Wohlfarth T, Storosum JG, Elferink AJA, et al. Response to tricyclic antidepressants: independent of gender? Am J Psychiatry. 2004;161(2):370–372. PubMed CrossRef
Zimmerman M, Chelminski I, Posternak MA. Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry. 2005;162(7):1370–1372. PubMed CrossRef
Sox HC, Lewis RJ. Pragmatic trials: practical answers to “real world” questions. JAMA. 2016;316(11):1205–1206. PubMed
Commission Expert Group on Safe and Timely Access to Medicines for Patients. Paper for STAMP meeting 10 March 2016: update on real world evidence data collection. 2016.
Olekhnovitch R, Hoertel N, Limosin F, et al. Using filled prescription sequences to rank antidepressants according to their acceptability in the general population: the Constances cohort. J Psychiatr Res. 2020;123:72–80. PubMed
Ouazana-Vedrines C, Lesuffleur T, Denis P, et al. Acceptability of second-line antidepressant medications using filled prescription sequences in a nationwide cohort study. J Clin Psychiatry. 2022;83(6):21m14248. PubMed
Ouazana-Vedrines C, Lesuffleur T, Denis P, et al. Using filled prescription sequences to rank antidepressants: a nationwide replication study. J Psychiatr Res. 2023;158:180–184. PubMed
Tuppin P, Rudant J, Constantinou P, et al. Value of a national administrative database to guide public decisions: from the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65(suppl 4):S149–S167. PubMed
Rey G, Jougla E, Fouillet A, et al. Ecological association between a deprivation index and mortality in France over the period 1997 – 2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health. 2009;9:33. PubMed
Rachas A, Gastaldi-Ménager C, Denis P, et al. The economic burden of disease in France from the national health insurance perspective: the healthcare expenditures and conditions mapping used to prepare the French social security funding act and the public health act. Med Care. 2022;60(9):655–664. PubMed CrossRef
Constantinou P, Tuppin P, Fagot-Campagna A, et al. Two morbidity indices developed in a nationwide population permitted performant outcome-specific severity adjustment. J Clin Epidemiol. 2018;103:60–70. PubMed CrossRef
Moore RA, Derry S, Aldington D, et al. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;2015(7):CD008242. PubMed CrossRef
Verhaak PFM, de Beurs D, Spreeuwenberg P. What proportion of initially prescribed antidepressants is still being prescribed chronically after 5 years in general practice? A longitudinal cohort analysis. BMJ Open. 2019;9(2):e024051. PubMed CrossRef
Hansen DG, Vach W, Rosholm JU, et al. Early discontinuation of antidepressants in general practice: association with patient and prescriber characteristics. Fam Pract. 2004;21(6):623–629. PubMed CrossRef
Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366. PubMed
Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010;71(10):1259–1272. PubMed CrossRef
Bebbington P, Dunn G, Jenkins R, et al. The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. Int Rev Psychiatry. 2003;15(1–2):74–83. PubMed
Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study. BMJ. 2018;361:k1951. PubMed CrossRef
Young EA, Midgley AR, Carlson NE, et al. Alteration in the hypothalamic pituitary-ovarian axis in depressed women. Arch Gen Psychiatry. 2000;57(12):1157–1162. PubMed CrossRef
Harlow BL, Wise LA, Otto MW, et al. Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry. 2003;60(1):29–36. PubMed
Bet PM, Hugtenburg JG, Penninx BWJH, et al. Side effects of antidepressants during long-term use in a naturalistic setting. Eur Neuropsychopharmacol. 2013;23(11):1443–1451. PubMed CrossRef
Clarke JG, Waring ME. Overweight, obesity, and weight change among incarcerated women. J Correct Health Care. 2012;18(4):285–292. PubMed CrossRef
Keers R, Aitchison KJ. Gender differences in antidepressant drug response. Int Rev Psychiatry. 2010;22(5):485–500. PubMed CrossRef
Noordam R, Aarts N, Tiemeier H, et al. Sex-specific association between antidepressant use and body weight in a population-based study in older adults. J Clin Psychiatry. 2015;76(6):e745–e751. PubMed CrossRef
Emslie C, Hunt K, Macintyre S. Perceptions of body image among working men and women. J Epidemiol Community Health. 2001;55(6):406–407. PubMed CrossRef
Tsai SA, Lv N, Xiao L, et al. Gender differences in weight-related attitudes and behaviors among overweight and obese adults in the United States. Am J Mens Health. 2016;10(5):389–398. PubMed CrossRef
Sattler KM, Deane FP, Tapsell L, et al. Gender differences in the relationship of weight-based stigmatisation with motivation to exercise and physical activity in overweight individuals. Health Psychol Open. 2018;5(1):2055102918759691. PubMed CrossRef